UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 3, 2019
Aclaris Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-37581 |
|
46-0571712 |
|
(State or other jurisdiction of |
|
(Commission File Number) |
|
(IRS Employer |
640 Lee Road, Suite 200
Wayne, PA 19087
(Address of principal executive offices, including zip code)
(484) 324-7933
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
Title of Each Class: |
|
Trading |
|
Name of Each Exchange on which Registered |
|
Common Stock, $0.00001 par value |
|
ACRS |
|
The Nasdaq Stock Market, LLC |
Indicate by check mark whether the registrant is an emerging growth Company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) Resignation of Chief Scientific Officer
On September 3, 2019, Stuart D. Shanler, M.D. notified Aclaris Therapeutics, Inc. (the “Company”), that he will resign as Chief Scientific Officer of the Company. Dr. Shanler is a co-founder of the Company. Pursuant to his employment agreement, the resignation will take effect on October 3, 2019, unless the Company and Dr. Shanler agree to an earlier date prior to October 3, 2019.
(e) Modified Compensation of Chief Executive Officer
On September 3, 2019, the Company’s board of directors approved a reduction of the annual base salary of Neal Walker, the Company’s Chief Executive Officer, from $566,500 per year to $300,000 per year, effective October 1, 2019. In connection with such reduction, the Company’s board of directors also resolved to grant an equity award to Dr. Walker, with the terms of such equity award to be subsequently determined by the Company’s compensation committee.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
ACLARIS THERAPEUTICS, INC. |
|
|
|
|
|
|
By: |
/s/ Frank Ruffo |
|
Date: September 9, 2019 |
|
Frank Ruffo |
|
|
|
Chief Financial Officer |